Published in Proc Natl Acad Sci U S A on May 02, 2005
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol (2006) 3.17
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
The many faces of tau. Neuron (2011) 2.89
Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med (2007) 2.14
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci (2011) 1.99
Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem (2007) 1.86
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J (2009) 1.68
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol (2010) 1.60
Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron (2012) 1.58
Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
New directions for frontotemporal dementia drug discovery. Alzheimers Dement (2007) 1.53
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J (2009) 1.40
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry (2016) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
Lithium protects against anesthesia-induced developmental neuroapoptosis. Anesthesiology (2009) 1.33
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain. Neurobiol Dis (2008) 1.24
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis (2011) 1.22
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol (2007) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest (2011) 1.20
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol (2011) 1.15
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol (2009) 1.14
Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging (2007) 1.14
Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener (2007) 1.13
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci (2012) 1.13
Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol (2008) 1.13
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol (2008) 1.12
GSK-3beta is required for memory reconsolidation in adult brain. PLoS One (2008) 1.11
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol (2010) 1.07
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing. Transl Psychiatry (2011) 1.04
Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One (2010) 1.03
Are tau aggregates toxic or protective in tauopathies? Front Neurol (2013) 1.03
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem (2009) 1.03
NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet (2011) 1.02
Mouse models of frontotemporal dementia. Ann Neurol (2012) 1.01
Lithium enhances remyelination of peripheral nerves. Proc Natl Acad Sci U S A (2012) 1.01
GSK3beta in ethanol neurotoxicity. Mol Neurobiol (2009) 1.01
Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis (2012) 0.99
Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med (2009) 0.99
Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse (2011) 0.99
Tau phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing mouse brain. Neurochem Res (2010) 0.99
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci (2014) 0.98
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) (2014) 0.98
Strategies for treatment in Alexander disease. Neurotherapeutics (2010) 0.98
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One (2013) 0.98
Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin. J Biol Chem (2009) 0.98
PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol (2015) 0.97
Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron (2014) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. Int J Alzheimers Dis (2011) 0.94
Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis (2011) 0.94
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One (2012) 0.93
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest (2010) 0.92
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci (2011) 0.91
Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med (2008) 0.91
The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther (2010) 0.91
Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem (2009) 0.90
GSK3 as a Sensor Determining Cell Fate in the Brain. Front Mol Neurosci (2012) 0.90
Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J Biol Chem (2011) 0.89
Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci (2014) 0.89
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol (2006) 0.89
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
Characteristics of tau oligomers. Front Neurol (2013) 0.89
GSK-3beta phosphorylation of functionally distinct tau isoforms has differential, but mild effects. Mol Neurodegener (2009) 0.89
Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci (2013) 0.88
The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel) (2013) 0.88
Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol (2009) 0.88
Tau Phosphorylation by GSK3 in Different Conditions. Int J Alzheimers Dis (2012) 0.87
TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. Biochem J (2011) 0.87
Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.87
Lithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin. J Biol Chem (2013) 0.85
Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 22.23
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J (1990) 6.23
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 4.26
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 2.65
Molecular targets of lithium action. Annu Rev Pharmacol Toxicol (2001) 2.63
Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A (1999) 2.41
Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging (2000) 2.40
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem (1997) 2.12
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun (2001) 2.08
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79
Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63
A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol (2004) 1.60
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57
Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci (1996) 1.49
Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol (2003) 1.44
Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett (1997) 1.44
Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience (1996) 1.33
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem (2004) 1.27
Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem (2002) 1.23
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Structure of tau protein and assembly into paired helical filaments. Biochim Biophys Acta (2000) 1.08
Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons. J Neurochem (1999) 1.08
Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Brain Res Mol Brain Res (1999) 1.04
Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice. Neurobiol Dis (2004) 1.03
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol (2003) 1.02
Following the leader: fibrillization of alpha-synuclein and tau. Exp Neurol (2004) 0.85
Lithium: a review of its pharmacokinetics, health effects, and toxicology. J Environ Pathol Toxicol Oncol (1994) 0.84
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res (2005) 11.02
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol (2005) 4.91
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 4.53
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron (2004) 4.21
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci (2004) 3.59
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 3.58
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med (2006) 2.78
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci (2007) 2.68
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Current progress of China's free ART program. Cell Res (2005) 2.59
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther (2005) 2.48
Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer (2012) 2.48
Electronic origin of high-temperature superconductivity in single-layer FeSe superconductor. Nat Commun (2012) 2.37
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Phase diagram and electronic indication of high-temperature superconductivity at 65 K in single-layer FeSe films. Nat Mater (2013) 2.34
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood (2003) 2.21
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol (2010) 2.20
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol (2002) 2.15
Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A (2004) 2.15
S-S synapsis during class switch recombination is promoted by distantly located transcriptional elements and activation-induced deaminase. Immunity (2007) 2.11
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet (2005) 2.08
Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis (2006) 2.07
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet (2012) 2.07
Experimental demonstration of topological surface states protected by time-reversal symmetry. Phys Rev Lett (2009) 1.99
Postoperative cognitive decline: where art tau? Anesthesiology (2012) 1.98
Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One (2009) 1.93
Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci (2003) 1.88
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet (2010) 1.83
Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci (2009) 1.83
15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81
A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp (2008) 1.80
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain (2009) 1.77
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol (2005) 1.77
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther (2009) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A (2002) 1.66
Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci (2008) 1.65
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest (2002) 1.63
BRI2 (ITM2b) inhibits Abeta deposition in vivo. J Neurosci (2008) 1.62
In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am (2003) 1.59
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron (2008) 1.59
Band structure engineering in (Bi(1-x)Sb(x))(2)Te(3) ternary topological insulators. Nat Commun (2011) 1.58
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2003) 1.58
Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci (2007) 1.58
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol (2011) 1.57